eBay Inc vs Mesoblast Limited — how do they compare? eBay Inc trades at $111.54 (market cap $50.07B), while Mesoblast Limited trades at $18.87 (market cap $2.31B). The key difference: eBay Inc is far larger — about 21.7× Mesoblast Limited's market cap, and eBay Inc pays a 1.1% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| EBAY | MESO | |
|---|---|---|
Market Cap | $50.07B | $2.31B |
Volume | 5,186,418 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $118.96 | $20.96 |
52-Week Low | $76.79 | $11.35 |
Enterprise Value | $53.41B | $2.32B |
Dividend Yield | 1.1% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Mesoblast (MESO) trades at $19.12, up 14.22% with strong bullish technical signals from moving averages. The biotech company shows promising commercial progress with FDA-approved Ryoncil generating $115M annual revenue, though fundamentals reveal significant losses with a -144.33% net income margin and negative EBITDA of -$80.06M. Recent milestones include achieving Phase 3 trial targets for chronic low back pain and receiving a BLA filing number for heart failure treatment.
Investment outlook balances high growth potential from Mesoblast's cellular medicine platform against substantial financial losses and valuation concerns. The company's transition to commercial operations and pipeline advancements present opportunities, while persistent cash burn and negative profitability represent key risks requiring careful monitoring of upcoming clinical and regulatory catalysts.
Trailing returns across standard periods
Latest headlines on both assets
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →